Carboplatin gynecological cancer

Lindemann K, Christensen RD, Vergote I, Stuart G, Izquierdo MA, Kaem J, et al. First-line treatment of advanced ovarian cancer with pacli-taxel/carboplatin with or without epirubicin (TEC vs TC)-a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG. Ann Oncol 2012 23(10) 2613-9. 

Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer a gynecologic oncology group study. J Clin Oncol 2003 21 3194-3200. 

MUd to moderate reduction in creatinine clearance with rises in serum urea and creatinine were reported in 14% of patients receiving carboplatin in a dose of 400 mg/m for gynecological malignancies. Of the patients who received carboplatin 400 mg/m with vincristine but without hydration for lung cancer, 19% developed renal changes. 

---